Methods and materials for treating diabetes or liver steatosis
This document provides methods and materials for treating diabetes and/or liver steatosis. For example, methods for using compositions containing a potato polysaccharide preparation to reduce one or more symptoms of diabetes or liver steatosis are provided. In some cases, a composition containing a potato polysaccharide preparation provided herein can be used to treat fatty liver disease.
1. A method for treating a fatty liver disease, wherein said method comprises:
(a) identifying a mammal with a fatty liver disease, and
(b) administering to said mammal a composition comprising a potato polysaccharide preparation obtained from homogenized raw potatoes, wherein said potato polysaccharide preparation is eluted from said homogenized raw potatoes with 10% acetonitrile, and wherein said potato polysaccharide preparation is a potato polysaccharide preparation that, when derivatized, results in at least the following acylated carbohydrates as assessed using gas chromatography/mass spectography:
(a) myo-inositol, set to 1× to serve as an internal standard,
(b) glucose at about 40× to about 60× the myo-inositol content,
(c) xylose at about 10× to about 20× the myo-inositol content,
(d) mannose at about 5× to about 15× the myo-inositol content, and
(e) galactose at about 3× to about 7× the myo-inositol content, wherein the severity of a symptom of said fatty liver disease is reduced.
2. The method of claim 1 , wherein said composition comprises said potato polysaccharide preparation in an amount that results in between 0.05 mg and 50 mg of the potato polysaccharide component of said potato polysaccharide preparation being administered to said mammal per kg of body weight of said mammal.
3. The method of claim 1 , wherein said composition comprises between 1 mg and 100 mg of said potato polysaccharide preparation.
4. The method of claim 1 , wherein said composition comprises between 6 mg and 20 mg of said potato polysaccharide preparation.
5. The method of claim 1 , wherein said composition comprises between 1 mg and 100 mg of the potato polysaccharide component of said potato polysaccharide preparation.
6. The method of claim 1 , wherein said composition comprises between 6 mg and 20 mg of the potato polysaccharide component of said potato polysaccharide preparation.
7. The method of claim 1 , wherein said composition is in the form of a tablet.
8. The method of claim 1 , wherein said composition comprises alpha lipoic acid.
9. The method of claim 1 , wherein said composition comprises alpha tocopherol.
10. The method of claim 1 , wherein said potato polysaccharide preparation is in an amount that results in between 0.075 mg and 0.5 mg of the potato polysaccharide component of said potato polysaccharide preparation being administered to said mammal per kg of body weight of said mammal.
11. The method of claim 1 , wherein at least about 80 percent of said potato polysaccharide preparation is potato polysaccharide.
12. The method of claim 1 , wherein at least about 90 percent of said potato polysaccharide preparation is potato polysaccharide.
13. The method of claim 1 , wherein at least about 95 percent of said potato polysaccharide preparation is potato polysaccharide.
14. The method of claim 1 , wherein said mammal is a human.
15. The method of claim 1 , wherein said potato polysaccharide preparation eluted from said homogenized raw potatoes with 10% acetonitrile is eluted from a C18 cartridge.
16. The method of claim 1 , wherein said potato polysaccharide preparation eluted from said homogenized raw potatoes is eluted from an HPLC peak at 3.5 minutes.